Nicox SA

Company Profile

• Business description

  Nicox SA is an international ophthalmology company developing solutions to help maintain vision and improve ocular health. Its program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

• Contact

  Rue Evariste Galois
  Emerald Square, Batiment C
  Sundesk Sophia Antipolis
  Biot06410
  FRA

  T: +33 497245300

  E: [email protected]

  https://www.nicox.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  14